WELCURE
Welcure Drugs & Pharmaceuticals financials
- Market cap
- ₹36 Cr
Quarterly results
Q4 FY26: revenue down 100.0%, net profit down 1766.7% against the same quarter last year.
| Line item | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 25 | 1 | 21 | 300 | 66 +164% | 0 −100% | 0 −100% |
| EBITDA | 0 | 2 | 0 | 1 | 31 | 11 +450% | 0 | -50 −5100% |
| Net profit | 0 | 2 | 0 | 3 | 23 | 8 +300% | 1 | -50 −1767% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance −76.3% 1Y
1Y: ₹0.93 on 9 Sept 2025 → ₹0.22. High ₹0.93 (9 Sept 2025), low ₹0.2 (27 Aug 2026).
Financials, as filed
| Year ending | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹0 Cr | ₹47 Cr | ₹366 Cr |
| Operating profit | ₹0 Cr | ₹3 Cr | ₹-8 Cr |
| Operating margin | — | 6.4% | -2.2% |
| Interest | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Depreciation | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Net profit | ₹0 Cr | ₹5 Cr | ₹-18 Cr |
| Net margin | — | 10.6% | -4.9% |
| Cash from operations | ₹0 Cr | ₹-222 Cr | ₹2 Cr |
| Free cash flow | ₹0 Cr | ₹-222 Cr | ₹2 Cr |
| ROCE | -13.0% | 3.0% | -3.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹12 Cr | ₹12 Cr | ₹13 Cr | ₹13 Cr | ₹112 Cr | ₹124 Cr |
| Reserves | ₹-12 Cr | ₹-12 Cr | ₹-12 Cr | ₹-12 Cr | ₹22 Cr | ₹-27 Cr |
| Borrowings | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹123 Cr | ₹0 Cr |
| Other liabilities | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹375 Cr | ₹413 Cr |
| Total liabilities | ₹0 Cr | ₹0 Cr | ₹2 Cr | ₹1 Cr | ₹633 Cr | ₹510 Cr |
| Fixed assets | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Capital work in progress | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹1 Cr |
| Other assets | ₹0 Cr | ₹0 Cr | ₹1 Cr | ₹1 Cr | ₹633 Cr | ₹509 Cr |
| Total assets | ₹0 Cr | ₹0 Cr | ₹2 Cr | ₹1 Cr | ₹633 Cr | ₹510 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Mar 2026
The ownership split has held steady since Mar 2025. The shareholder count grew 172% to 87,977.
- Public
- 100.0%
Since Mar 2025
- Public +0.02 pp
- Promoters 0.00 pp
- DIIs 0.00 pp
How it drifted, 12 quarters
Ownership split by quarter, oldest first. Jun '23: Public 100.0%.Sep '23: Public 100.0%.Dec '23: Public 100.0%.Mar '24: Public 100.0%.Jun '24: Public 100.0%.Sep '24: Public 100.0%.Dec '24: Public 100.0%.Mar '25: Public 100.0%.Jun '25: Public 100.0%.Sep '25: Public 100.0%.Dec '25: Public 100.0%.Mar '26: Public 100.0%.
Who is on the register
Named in the Mar 2026 filing
Every holder of Welcure Drugs & Pharmaceuticals ltd above SEBI's 1% disclosure line, and what changed since Dec 2025.
| Holder | Stake | Change |
|---|---|---|
| Kifs Trade Capital Private Limited | — | off the list |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Learn to analyse Welcure Drugs & Pharmaceuticals ltd
Guides on how to read this kind of business and the numbers that matter.